Download PDF
Aktuelle Urol 2000; 31(7): 403-412
DOI: 10.1055/s-2000-9484
ÜBERSICHT
Georg Thieme Verlag Stuttgart · New York

Molekulare Aspekte des Harnblasenkarzinoms III: Gentherapie des Harnblasenkarzinoms

Gene Therapy of Bladder CancerP. Ardelt1, 2 , A. Böhle2
  • 1Genitourinary Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030
  • 2Laborgruppe Immuntherapie, Forschungszentrum Borstel u. Klinik für Urologie, Med. Universität Lübeck
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Gentherapie von Tumorerkrankungen ist die logische Folge der intensiven Bemühungen um die Aufklärung der genetischen Grundstruktur des Lebens und zu Krankheiten führender genetischer Defekte. Gentherapeutische Verfahren erlauben erstmals eine kausale Therapie des zu einer Erkrankung führenden Gendefekts. Die Gentherapie ist definitionsgemäß die Behandlung einer erworbenen oder angeborenen Krankheit durch Transfer von genetischem Material. - Dieser Artikel fasst die Grundlagen und Fortschritte in der Behandlung von Blasenkarzinomen durch Gentherapie zusammen und stellt sie systematisch dar. Verschiedene therapeutische Ansätze wurden entwickelt, wie z. B. der Transfer von Tumorsuppressorgenen zur Wiederherstellung der Zellzykluskontrolle in Tumorzellen, Suizid-Gentherapie zur selektiven Abtötung von Tumorzellen, Modulation des Immunsystems zur Induktion oder Verstärkung einer Immunantwort gegen den Tumor. Obwohl klinisch derzeit kein Verfahren etabliert ist, müssen die Fortschritte in der Gentherapie des Harnblasenkarzinoms aufgrund des hohen therapeutischen Potenzials aufmerksam verfolgt werden.

Abstract

Cancer gene therapy is an important consequence of the intense studies on the genetic base of life and genetic defects leading to diseases. Gene therapy firstly offered the ability to treat the actual gene defect leading to a disease. In the common definition gene therapy is the treatment of an acquired or inherited disease by transfer of genetic material. - This article reviews the basis and progresses in treating bladder cancer by gene therapy. Various therapeutic approaches have been developed for this, such as transfer of tumor suppressor genes to restore cell cycle control in tumor cells, suicide gene therapy to selectively eliminate tumor cells, modulation of immune response to enhance or initiate an immune response against a bladder tumor to name only a few. Although clinically none of these have been established the progresses should be thoroughly traced.

Key words:

Urogenital neoplasms - Bladder neoplasms - Gene therapy

Literatur

  • 1 Avery O T, McLeod C M, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a deoxyribonucleic acid fraction isolated from Pneumococcus type III.  J Exp Med. 1944;  79 137-158
    CrossrefPubMedGoogle Scholar
  • 2 Kmiec E B. Genomic targeting and genetic conversion in cancer therapy.  Semin Oncol. 1996;  23 (1) 188-193
    PubMedGoogle Scholar
  • 3 Kren B T, Cole-Strauss A, Kmiec E B, Steer C J. Target nucleotide exchange in the alkaline phosphatase gene of HuH-7 cells mediated by a chimeric RNA/DNA oligonucleotide.  Hepatology. 1997;  25 (6) 1462-1468
    CrossrefPubMedGoogle Scholar
  • 4 Yanez R J, Porter A C. Gene targeting is enhanced in human cells overexpressing hRAD51.  Gene Therapy. 1999;  6 (7) 1282-1290
    CrossrefPubMedGoogle Scholar
  • 5 Juliano R L, Akhtar S. Liposomes as drug delivery system for antisense oligonucleotides.  Antisense Res Dev. 1992;  2 165-176
    PubMedGoogle Scholar
  • 6 Chavany C D, Le D T, Couvreur P, Puisieux F, Helene C. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides.  Pharm Res. 1992;  9 441-449
    CrossrefPubMedGoogle Scholar
  • 7 Belair C D, Yeager T R, Lopez P M, Reznikoff C A. Telomerase activity: a biomarker of cell proliferation, not malignant transformation.  Proc Natl Acad Sci. 1997;  94 (25) 13677-13682
    CrossrefPubMedGoogle Scholar
  • 8 Lim B, Apperley J F, Orkin S H, Williams D A. Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells.  Proc Nat Acad Sci. 1989;  86 (22) 8892-8896
    PubMedGoogle Scholar
  • 9 Wang J, Ma Y, Knechte S J. Adenovirus-mediated gene transfer into rat cardiac allografts. Comparison of direct injection and perfusion.  Transplant. 1996;  61 (12) 1726-1729
    PubMedGoogle Scholar
  • 10 Li Y, Pong R C, Bergelson J M, Hall M C, Sagalowsky A I, Tseng C P, Wang Z, Hsieh J T. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy.  Cancer Res. 1999;  59 (2) 325-330
    PubMedGoogle Scholar
  • 11 Pan C X, Koeneman K S. A novel tumor-specific gene therapy for bladder cancer.  Med Hypotheses. 1999;  53 (2) 130-135
    PubMedGoogle Scholar
  • 12 Brandau S, Böhle A. Molekulare und genetische Mechanismen bei der Entstehung des Harnblasenkarzinoms.  Akt Urol. 2000;  31 149-156
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Morris Jr B D, Drazan K E, Csete M E, Werthman P E, Van Bree M P, Rosenthal J T, Shaked A. Adenoviral-mediated gene transfer to bladder in vivo.  J Urol. 1994;  152 (2 Pt 1) 506-509
    PubMedGoogle Scholar
  • 14 Lee S S, Eisenlohr L C, McCue P A, Mastrangelo M J, Lattime E C. Intravesical gene therapy: in vivo gene transfer using recombinant vaccina virus vectors.  Cancer Res. 1994;  54 (13) 3325-3328
    PubMedGoogle Scholar
  • 15 Bass C, Cabrera G, Elgavish A, Robert B, Siegal G P, Anderson S C, Maneval D C, Curiel D T. Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo.  Cancer Gene Ther. 1995;  2 (2) 97-104
    PubMedGoogle Scholar
  • 16 Harimoto K, Sugimura K, Lee C R, Kuratsukuri K, Kishimoto T. In vivo gene transfer methods in the bladder without viral vectors.  Br J Urol. 1998;  81 (6) 870-874
    PubMedGoogle Scholar
  • 17 Chen L, Chen D, Block E, O'Donnell M, Kufe D W, Clinton S K. Eradication of murine bladder carcinoma by intratumor injection of a biscistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer.  J Immunol. 1997;  159 351-359
    PubMedGoogle Scholar
  • 18 Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells.  Exp Med. 1993;  177 (4) 1127-1134
    PubMedGoogle Scholar
  • 19 Horiguchi Y, Larchian W A, Kaplinsky R, Fair W R, Heston W D. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.  Gene Therapy. 2000;  7 (10) 844-851
    CrossrefPubMedGoogle Scholar
  • 20 Yamanaka K, Hara I, Nagai H, Miyake H, Gohji K, Micallef M J, Kurimoto M, Arakawa S. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model.  Cancer Immunol Immunother. 1999;  48 (6) 297-302
    PubMedGoogle Scholar
  • 21 Milella M, Jacobelli J, Cavallo F, Guarini A, Velotti F, Frati L, Foa R, Forni G. Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder.  Br J Cancer. 1999;  79 (5 - 6) 770-779
    CrossrefPubMedGoogle Scholar
  • 22 Garrido F, Ruiz-Cabello F. MHC expression of human tumors - its relevance for local tumor growth and metastasis.  Semin Cancer Biol. 1991;  2 (1) 3-10
    PubMedGoogle Scholar
  • 23 Saito S, Bannerji R, Gansbacher B, Rosenthal F M, Romanenko P, Heston W D, Fair W R, Gilboa E. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines.  Cancer Res. 1994;  54 (13) 3516-3520
    PubMedGoogle Scholar
  • 24 Gueguen M, Patard J J, Gaugler B, Brasseur F, Renault J C, Van Cangh P J, Boon T, Van den Eynde B J. An antigen recognized by autologous CTLs on a human bladder carcinoma.  J Immunol. 1998;  160 (12) 6188-6194
    PubMedGoogle Scholar
  • 25 Moolten F L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy.  Cancer Res. 1986;  46 (10) 5276-5281
    PubMedGoogle Scholar
  • 26 Sutton M A, Berkman S A, Chen S H, Block A, Dang T D, Kattan M W, Wheeler T M, Rowley D R. Adenovirus-mediated suicide gene therapy for experimental bladder cancer.  Urology. 1997;  49 (2) 173-180
    CrossrefPubMedGoogle Scholar
  • 27 Mullen C A, Kilstrup M, Blaese R M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-florocytosine: a negative selection system.  Proc Natl Acad Sci. 1992;  89 33-37
    PubMedGoogle Scholar
  • 28 Hughes B W, Wells A H, Bebok Z. Bystander killing of melanoma cells using the human tyrosinase promotor to express the Escherichia coli purine nucleoside phosphorylase gene.  Cancer Res. 1995;  55 3339-3345
    PubMedGoogle Scholar
  • 29 Freeman S M, Abboud C N, Whartenby K A, Packman C H, Koeplin D S, Moolten F L, Abraham G N. The „bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified.  Cancer Res. 1993;  53 (21) 5274-5283
    PubMedGoogle Scholar
  • 30 Freije J M, MacDonald N J, Steeg P S. Nm 23 and tumour metastasis: a basic and translational advances.  Biochem Soc Symp. 1998;  63 261-271
    PubMedGoogle Scholar
  • 31 Huang Y W, Baluna R, Viretta E S. Adhesion molecules as targets for cancer therapy.  Histology and histopathology. 1997;  12 467-477
    PubMedGoogle Scholar
  • 32 Xu H J, Zhou Y, Seigne J, Perng G S, Mixon M, Zhang C, Li J, Benedict W F. Enhanced tumor suppressor gene therapy via replication-deficient protein. Adenovirus vectors expressing an N-terminal truncated retinoblastoma.  Cancer Res. 1996;  56 (10) 2245-2249
    PubMedGoogle Scholar
  • 33 Li J, Hu S X, Perng G S, Zhou Y, Xu K, Zhang C, Seigne J, Benedict W F, Xu H J. Expression of the retinoblastoma (RB) tumor suppressor gene inhibitis tumor cell invasion in vitro.  Oncogene. 1996;  13 (11) 2379-2386
    PubMedGoogle Scholar
  • 34 Feng M, Cabrera G, Deshane J, Scanlon K J, Curiel D T. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme.  Cancer Res. 1995;  55 (10) 2024-2028
    PubMedGoogle Scholar
  • 35 Irie A, Anderegg B, Kashani-Sabet M, Ohkawa T, Suzuki T, Halks-Miller M, Curiel D T, Scanlon K J. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer.  Antisense nucleic acid drug dev. 1999;  9 (4) 341-349
    PubMedGoogle Scholar
  • 36 Grim J, D'Amico A, Frizelle S, Zhou J, Kratzke R A, Curiel D T. Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel.  Clin Cancer Res. 1997;  3 (12 Pt 1) 2415-2423
    PubMedGoogle Scholar
  • 37 Tanaka M, Sazawa A, Shinohara N, Kobayashi Y, Fujioka Y, Koyanagi T, Kuzumaki N. Gelsolin gene therapy by retrovirus producer cells for human bladder cancer in nude mice.  Cancer Gene Ther. 1999;  6 (5) 482-487
    CrossrefPubMedGoogle Scholar
  • 38 Hall M C, Li Y, Pong R C, Ely B, Sagalowsky A I, Hsieh J T. The growth inhibitory effect of p21 adenovirus on human bladder cancer cells.  J Urol. 2000;  163 (3) 1033-1038
    PubMedGoogle Scholar
  • 39 Stein J P, Ginsberg D A, Grossfeld G D, Esrig D, Dickinson M G, Groshen S, Taylor C R, Skinner D G. The significance of p21 WAF1/CIP1 expression and tumor progression in bladder cancer.  J Urol. 1997;  157 (suppl) 161 A
    PubMedGoogle Scholar
  • 40 Koc O N, Allay J A, Lee K, Davis B M, Reese J S, Gerson S L. Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance.  Semin Oncol. 1996;  23 (1) 46-65
    PubMedGoogle Scholar
  • 41 Sorrentino B P, Brand S J, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis A W. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR 1.  Science. 1992;  257 (5066) 99-103
    PubMedGoogle Scholar
  • 42 Cline M J. Gene transfer in intact animals.  Nature. 1980;  284 422-425
    CrossrefPubMedGoogle Scholar
  • 43 Mercola K E, Stang H D, Browne J, Salser J, Cline M J. Insertion of a new gene of viral origin into bone marrow cells of mice.  Science. 1980;  208 1033-1035
    PubMedGoogle Scholar

Prof. Dr. med A Böhle

Klinik für Urologie Medizinische Universität zu Lübeck

Ratzeburger Allee 160 23538 Lübeck

Phone: Tel. +49-451-500-6112

Fax: Fax +49-451-500-6112

      >